Phase 3 Colorectal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- The patient, or a family member on their behalf, is willing to agree to take part and sign a consent form
- Aged between 18 and 75 years old, of any gender
- Diagnosed with locally advanced rectal cancer (a specific type called adenocarcinoma), confirmed by a tissue sample
- Tumour testing (by protein staining and/or genetic testing) has confirmed a specific tumour type known as pMMR or MSS
- The lower edge of the tumour is within 10 cm of the opening of the back passage
- Physically well enough to carry out normal daily activities with little or no limitation (a standard fitness scale used in cancer care rates this as 0 or 1)
- Has not previously received any treatment for rectal cancer, including radiation, chemotherapy, or surgery
- No medical reasons that would prevent surgery
- Blood and organ function test results fall within the required ranges, including healthy levels of white blood cells, neutrophils, platelets, haemoglobin, liver enzymes, bilirubin, kidney function, and blood clotting measures (confirm specific values with trial site)
- Urine protein levels are within an acceptable range at the start of the study
Who may not be able to join:
- People whose tumour testing shows a different tumour type known as MSI-H or dMMR
- People who have previously received any form of immunotherapy, including immune checkpoint inhibitors, immune checkpoint activators, immune cell therapies, or any other treatment designed to alter the immune system's response to the tumour
- People with any other illness, condition, laboratory result, or history of substance use that, in the treating doctor's judgement, could affect the person's safety, their ability to give informed consent, their ability to follow the study requirements, or the accuracy of safety assessments during the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Zhenyu Lin, MD, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phone: 027-85871982
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
3-year event-Free Survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.